| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/27/2001 | US6207717 Entrapment of vitamins with an elastomeric silicone polyether |
| 03/27/2001 | US6207696 Compositions and methods for the prophylaxis and treatment of dysmenorrhea, endometriosis, and pre-term labor, using histidine |
| 03/27/2001 | US6207673 For cancer therapy |
| 03/27/2001 | US6207661 Premixed formulation of piperacillin sodium and tazobactam sodium injection |
| 03/27/2001 | US6207660 Texaphyrin conjugates and uses thereof |
| 03/27/2001 | US6207653 Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus |
| 03/27/2001 | US6207646 Immunostimulatory nucleic acid molecules |
| 03/27/2001 | US6207638 For enhancing and extending post meal satiety by stimulating cholecystokinin levels in a calorically efficient manner for reducing weight, comprising protein consisting of casein, whey and soy, glycomacropeptide, long chain fatty acids, fibers |
| 03/27/2001 | US6207456 Nucleic acid delivery vehicle |
| 03/27/2001 | US6207417 DNA encoding stem cell factor |
| 03/27/2001 | US6207401 Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
| 03/27/2001 | US6207398 Lysing red blood cells in a sample of whole blood containing cyclosporin a, contacting the sample with excess of labeled anti-cyclosporin antibody to form a complex, separating unbound antibody, contacting complex with cyclosporins |
| 03/27/2001 | US6207198 Omeprazole core comressed together with inert nuclei coated with a polymeric intermediatel layer overcoated with an enteric layer; stabilization |
| 03/27/2001 | US6207197 Microsphere comprising a drug-containing inner core, water insoluble polymeric rate controlling layer, and a bioadhesive outer layer of cationic polymer; treatment of helicobacter pylori |
| 03/27/2001 | US6207195 Sodium 4-phenylbutyrate in solid nanosphere formed by coacervation of a polycation, i.e., a protein and a polyanion, i.e., a nucleic acid; treatment of cystic fibrosis |
| 03/27/2001 | US6207192 Prolongation of chemical activity of flavorants and therapeutics with cetyl pyridinium chloride |
| 03/27/2001 | US6207191 Time-release capsule including a fluid permeable, drug-containing inner chamber having its opening plugged with a viscoelastic polymer which slides out of the way to release the drug when the interior fluid pressure increases in situ |
| 03/27/2001 | US6207186 Lamellar gels and methods for making and using |
| 03/27/2001 | US6207180 Intravesical drug delivery |
| 03/27/2001 | US6207173 Lysine derivatives containing an Nε-alkoxy or Nε-alkenoxycarbonyl group, their preparation and their use in cosmetic, pharmaceutical, hygiene or food compositions |
| 03/27/2001 | US6207172 Liquids; mixture of water, polyethylene glycol, polyvinylpyrrolidone, buffer and drug |
| 03/27/2001 | US6207153 Antigen binding polypeptide |
| 03/27/2001 | US6207151 Increasing solubility; mixing phosphate buffer and anionic polymer |
| 03/27/2001 | US6207133 Anti-tumoral therapy agent containing a contrast agent |
| 03/27/2001 | CA2277722C Water dispersible tablets |
| 03/27/2001 | CA2123118C Anhydrous topical compositions which dry rapidly on contact |
| 03/27/2001 | CA2072623C Bioadhesive composition and patch |
| 03/22/2001 | WO2001020013A2 Viral replicons and viruses dependent on inducing agents |
| 03/22/2001 | WO2001019901A2 Process for making aqueous coated beadlets |
| 03/22/2001 | WO2001019871A2 Delivery system for antidandruff agent |
| 03/22/2001 | WO2001019838A1 Macrocyclic chelants for metallopharmaceuticals |
| 03/22/2001 | WO2001019408A1 Nucleic acids encoding polyepitope polypeptides |
| 03/22/2001 | WO2001019407A2 Taxane prodrugs |
| 03/22/2001 | WO2001019406A2 Amphiphilic prodrugs |
| 03/22/2001 | WO2001019405A2 Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
| 03/22/2001 | WO2001019401A1 Method for producing a tablet made of isomaltulose, isomalt or isolmalt variants |
| 03/22/2001 | WO2001019391A1 Topical treatment of streptococcal infections |
| 03/22/2001 | WO2001019383A1 Stable carotene-xanthophyll beadlet compositions and methods of use |
| 03/22/2001 | WO2001019378A2 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols |
| 03/22/2001 | WO2001019372A1 Formulations for parenteral use of estramustine phosphate and amino acids |
| 03/22/2001 | WO2001019366A1 Topical treatment for prevention of ocular infections |
| 03/22/2001 | WO2001019363A1 Directly compressible, ultra fine acetaminophen compositions and process for producing same |
| 03/22/2001 | WO2001019362A2 Formulations for treating or preventing mucositis |
| 03/22/2001 | WO2001019356A2 High lipid diet |
| 03/22/2001 | WO2001019354A2 Composition for ivf |
| 03/22/2001 | WO2001019348A1 Stabilization of enalapril maleate with maleic acid |
| 03/22/2001 | WO2001019345A1 Method to obtain microparticles |
| 03/22/2001 | WO2001019342A2 Pharmaceutical formulation of fluticasone propionate |
| 03/22/2001 | WO2001019341A1 Method for modulating the metabolism of nitrogen oxides, compositions therefor (and variants) and method for acting on a patient's organism necessitating the metabolism of nitrogen oxides to be corrected |
| 03/22/2001 | WO2001019340A1 Dispersion formulations containing lipase inhibitors |
| 03/22/2001 | WO2001019339A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 03/22/2001 | WO2001019338A1 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| 03/22/2001 | WO2001019337A2 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing |
| 03/22/2001 | WO2001019336A1 Galenic formulations fast disintegrating in the mouth and method for preparing same |
| 03/22/2001 | WO2001019335A2 Composition to be administered through mucous membrane |
| 03/22/2001 | WO2001019334A2 Pharmaceutical solutions of levosimendan |
| 03/22/2001 | WO2001019329A2 Polyoxyalkylene copolymers containing pourable liquid vehicles |
| 03/22/2001 | WO2001019320A2 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | WO2001019305A1 Water absorbent keratin and gel formed therefrom |
| 03/22/2001 | WO2001019208A1 Directly compressable raw material for tablets |
| 03/22/2001 | WO2001019191A1 Method for the production of polyvinylpyrrolidone-iodine in an aqueous solution |
| 03/22/2001 | WO2001008661A3 Opioid sustained-released formulation |
| 03/22/2001 | WO2000069421A3 Transdermal therapeutic system (tts) containing tolterodine |
| 03/22/2001 | WO2000052037A8 Echinocandin/carbohydrate complexes |
| 03/22/2001 | WO2000030607A8 PHARMACEUTICAL AEROSOL COMPOSITION CONTAINING HFA 227 AND HFA 134a |
| 03/22/2001 | WO1999063936A8 Novel therapeutic agents that modulate endothelin receptors |
| 03/22/2001 | DE19944464A1 Verfahren zur Herstellung von Polyvinylpyrrolidon-lod in wässriger Lösung A process for preparing polyvinylpyrrolidone-iodine in aqueous solution |
| 03/22/2001 | DE19944137A1 O/W-Emulsionen mit einem Gehalt an einem oder mehreren Biochinonen und einem erhöhten Gehalt an Glycerin O / W emulsions with a content of one or more bioquinones and an elevated content of glycerol |
| 03/22/2001 | CA2637770A1 Process for manufacturing a pharmaceutical chewing gum |
| 03/22/2001 | CA2386530A1 Viral replicons and viruses dependent on inducing agents |
| 03/22/2001 | CA2386525A1 Method for modulating the metabolism of nitrogen oxides, compositions therefor (and variants) and method for acting on a patient's organism necessitating the metabolism of nitrogen oxides to be corrected |
| 03/22/2001 | CA2385065A1 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins |
| 03/22/2001 | CA2385063A1 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
| 03/22/2001 | CA2384987A1 Nucleic acids encoding polyepitope polypeptides |
| 03/22/2001 | CA2384876A1 Composition to be administered through mucous membrane |
| 03/22/2001 | CA2384726A1 Formulations for parenteral use of estramustine phosphate and amino acids |
| 03/22/2001 | CA2384646A1 Taxane prodrugs |
| 03/22/2001 | CA2384645A1 Amphiphilic prodrugs |
| 03/22/2001 | CA2384429A1 Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
| 03/22/2001 | CA2383405A1 Process for making aqueous coated beadlets |
| 03/22/2001 | CA2383038A1 Topical treatment of streptococcal infections |
| 03/22/2001 | CA2382908A1 Composition for ivf |
| 03/22/2001 | CA2382633A1 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | CA2382057A1 Macrocyclic chelants for metallopharmaceuticals |
| 03/22/2001 | CA2382008A1 Stable carotene-xanthophyll beadlet compositions and methods of use |
| 03/22/2001 | CA2382005A1 Method to obtain microparticles |
| 03/22/2001 | CA2350675A1 Galenic formulations fast disintegrating in the mouth and method for preparing same |
| 03/21/2001 | EP1084717A1 Pleiotrophin-based compositions for enhancing connective tissue repair |
| 03/21/2001 | EP1084701A1 O/W-emulsion comprising one or several bioquinones and an elevated amount of glycerine |
| 03/21/2001 | EP1084693A1 $g(a)-HYDROXY FATTY ACID DERIVATIVES AND COMPOSITION FOR EXTERNAL USE CONTAINING THE SAME |
| 03/21/2001 | EP1084625A2 Flavor delivery system |
| 03/21/2001 | EP1084270A1 Inhibition of coagulation in blood and blood products |
| 03/21/2001 | EP1084246A2 Biological material for preparing pharmaceutical compositions for treating mammals |
| 03/21/2001 | EP1084214A1 Contaminant reduced marine oil |
| 03/21/2001 | EP1084172A1 Polyamino acid vesicles |
| 03/21/2001 | EP1084170A1 Polyethylene glycol-polyorthoester, polyethylene glycol-polyorthoester-polyethylene glycol, and polyorthoester-polyethylene glycol-polyorthoester block copolymers |
| 03/21/2001 | EP1084149A1 Acylated alkylated cyclodextrin derivatives and their use as carriers for medicaments |
| 03/21/2001 | EP1084146A2 Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
| 03/21/2001 | EP1084145A2 Antibodies to the ed-b domain of fibronectin, conjugates containing them and use thereof for diagnosis and therapy of tumors and diseases associated with angiogenesis |
| 03/21/2001 | EP1083937A1 Radioioinated phenols for brachytherapy |